研究单位：[1]Shanghai Pharmaceuticals Holding Co., Ltd[2]The First Affiliated Hospital，Sun Yat-sen University,Guangzhou,Guangdong,China,510080[3]The Sixth Affiliated Hospital, Sun Yat-sen University,Guangzhou,Guangdong,China,510655[4]The Third Affiliated Hospital of Guangzhou Medical University,Guangzhou,Guangdong,China[5]Huizhou First Hospital,Huizhou,Guangdong,China[6]The Second Hospital of Hebei Medical University,Shijiazhuang,Hebei,China[7]The First Affiliated Hospital of Zhengzhou University,Zhengzhou,Henan,China[8]Union Hospital Tongji Medical College Huazhong Universitu of Science and Technology,Wuhan,Hubei,China,430000[9]Tongji Hospital Tongji Medical College of Huazhong University of Science and Technology,Wuhan,Hubei,China,430030[10]Renmin Hospital of Wuhan University,Wuhan,Hubei,China,430060[11]The First Affiliated Hospital of University of South China,Hengyang,Hunan,China,675299[12]The Affiliated Hospital of Xuzhou Medical University,Xuzhou,Jiangsu,China,221000[13]Shengjing Hospital affiliated to China Medical University,Shenyang,Liaoning,China,110136[14]General Hospital of Ningxia Medical University,Yinchuan,Ningxia,China,750004[15]Beijing Chao-Yang Hospital,Capital Medical University,Beijing,China,100020[16]Peking University Third Hospital,Beijing,China[17]Chifeng Municipal Hospital,Chifeng,China[18]The First Affiliated Hospital, Zhejiang University School of Medicine,Hangzhou,China,310003[19]Shanghai Jiaotong University School of Medicine, Renji Hospital,Shanghai,China,200001[20]Tianjin Medical University General Hospital[21],Tianjin,China,300052
研究目的：
To preliminarily evaluate the clinical efficacy of the renin inhibitor SPH3127 Tablets in patients with mild to moderate ulcerative colitis with placebo as a control and determine the recommended dose.
